ALL Hub continues to enhance global knowledge of acute lymphoblastic leukemia throughout 2021

Press Release: Available for Immediate Release

The ALL Hub, run by Scientific Education Support (SES) in partnership with the European School of Haematology (ESH), has continued to promote significant developments in the treatment and research of acute lymphoblastic leukemia (ALL) throughout Quarter 2 of 2021.

The ALL Hub is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in ALL. In Quarter 2, the ALL Hub provided live coverage from several virtual events, highlighting the key developments in ALL research.

Reviewing the ALL Hub’s activity, Mia Hill, IME director at Scientific Education Support, said:

“The ALL Hub’s aim is to enhance knowledge of ALL through multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management. To achieve this, the ALL Hub shares novel, evidence-based articles, drug and trial updates, and expert opinions. Our work allows us to disseminate international congress coverage to clinicians and scientists around the world.

In April, the ALL Hub attended the 2021 Korean Society of Hematology International Conference & 62nd Annual Meeting (ICKSH 2021), the Acute Leukemia Forum 2021, and the American Society of Pediatric Hematology/Oncology (ASPHO) Conference. We attended the European School of Hematology (ESH) 2nd Translational Research Conference: Acute Lymphoblastic Leukemia in May. In June, the ALL Hub attended the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2021 Virtual Congress.

During these meetings, the ALL Hub provided live coverage of sessions and produced articles on the cutting-edge research presented by key experts in the field. By attending these events, we can provide every treatment team and researcher with instant access to expert opinions and the latest evidence-based information on ALL, which we believe will aid treatment decisions and improve the lives of patients with ALL, globally.

Everyone at the ALL Hub would like to thank its supporters —Novartis and Amgen—without whom the platform would not be possible.”

For more information on the ALL Hub, please visit lymphoblastic-hub.com.

For media enquiries or to explore collaboration opportunities, please contact or is a type of cancer that affects white blood cells. It progresses quickly and aggressively and requires immediate treatment. Both adults and children can be affected.

ALL is rare, with around 790 people diagnosed with the condition each year in the UK. Most cases develop in children, teenagers, and young adults.

Although it is rare, ALL is the most common type of leukemia affecting children—around 85% of childhood cases occur in individuals younger than 15 years of age (mostly between the ages of 0 and 5). ALL affects slightly more boys than girls.

About the ALL Hub

The ALL Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in ALL. Our aim is to enhance knowledge in ALL through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

The ALL Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies the ALL Hub supports HCPs worldwide.

The ALL Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

The ALL Hub was founded in partnership with the European School of Haematology (ESH) in 2021 and is guided by an international steering committee of experts in the field of ALL. The steering committee meets regularly to discuss the performance of the ALL Hub and to devise action plans on how best to support the ALL community and address any unmet educational needs.

Funding for our hubs are made possible through financial support from the pharmaceutical industry. ​All content is developed by SES in collaboration with an expert Steering Committee.​All content is independent, and the educational supporters are allowed no influence on the content.​

If you are interested in becoming an ALL supporter, please contact is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘KNOW’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, which includes the Lymphoma Hub, AML Hub, Multiple Myeloma Hub, GvHD Hub, MPN Hub, and MDS Hub.

About the European School of Haematology (ESH)

The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in hematology and related disciplines at the European level. ESH conferences present the latest science and insight into new developments in the fields of basic, clinical, and therapeutic research in hematology.